Diabetes, GLP-1, and Lipid Reduction
Michael Blaha, MD, highlights the potential of GLP-1 agonists in lowering LDL cholesterol, triglycerides, and body weight in patients with diabetes, presenting them as an additional option for reducing cardiovascular risk in this patient population.
Read More
REDUCE-IT Trial and Triglyceride-Lowering Agents
The panel of medical experts addresses the challenges in raising awareness among healthcare providers about various medications and the need for increased awareness of the REDUCE-IT trial outcomes.
Read More
Other Notable Emerging Lipid-Lowering Treatments
Erin Michos, MD, highlights several notable emerging lipid-lowering treatments, including bempedoic acid, the ANGPTL3 inhibitor evinacumab, the MTP inhibitor lomitapide, the ApoB-100 inhibitor mipomersen, and the ApoC-III degradation molecules volanesorsen and olezarsen.
Read More
Examining Results from VICTORION-INITIATE Trial
Michael Koren, MD, discusses the recently released results from the VICTORIAN-INITIATE (V-INITIATE) trial, which were presented at the 2024 American College of Cardiology (ACC) Annual Scientific Session in Atlanta.
Read More
Evaluating Safety of Novel LDL Management Mechanism
Deepak Bhatt, MD, MPH, MBA, reviews the efficacy and safety data of inclisiran, highlighting its long-term effects and noting that injection site reactions are among the most prominent adverse reactions associated with this medication.
Read More
Optimizing PCSK9 Inhibitors and Analyzing Plaque Reduction Data
Michael Blaha, MD, discusses the efficacy and safety of novel targeted therapies for lowering LDL cholesterol and emphasizes the importance of long-term data in building patient confidence in this new treatment option.
Read More
Innovations in Small Interfering RNA (siRNA) Therapy
Leading experts highlight the established role of PCSK9 inhibitors, such as evolocumab and alirocumab, and introduce the promising second-generation PCSK9 inhibitors, known as small interfering RNA (siRNA), which represent an innovative therapeutic approach that selectively reduces the production of specific proteins through RNA interference.
Read More
Ongoing Lp(a) Trials and Clinical Approaches to Treatment
Panelists discuss ongoing clinical trials aimed at lowering Lipoprotein(a) levels, emphasizing the importance of proactive patient testing, and referring to new guidelines recommending that everyone be tested once in their lifetime.
Read More
Stricter LDL-C Targets: Explaining Goalpost Changes to Patients
Key opinion leaders in cardiology share insights on reducing LDL cholesterol to manage cardiovascular disease risk, educating patients not reaching goals, and implementing real-world clinical strategies for maintaining lower LDL levels.
Read More
Overview of Low-Density Lipoprotein Cholesterol Management
Erin Michos, MD, delivers a comprehensive review of lipid management and its influence on cardiovascular disease, emphasizing recent studies that underscore the need for improved treatment strategies for high-risk patients.
Read More
Key Takeaways for Lipid Lowering in Hypercholesterolemia and ASCVD
Drs Erin Michos, Pam Taub, Robert Busch, Alison Bailey, and Jorge Plutzky offer key takeaways in the management of hypercholesterolemia and ASCVD.
Read More
Barriers and Solutions for Lipid Management in Clinical Practice
An expert panel discusses challenges and provides solutions to managing patients with hypercholesterolemia.
Read More
Multidisciplinary/Team Based Approach for Lipid Management
Our panel highlights the importance of a team-based approach to care in the management of hypercholesterolemia.
Read More
The Role of Combination Therapy in Hypercholesterolemia
Erin D. Michos, MHS, FACC, FASPC; Pam Taub, MD, FACC, FASPC; Robert Busch, MD; Alison Bailey, MD, FACC; and Jorge Plutzky, MD; share benefits of combination therapy for lipid lowering in ASCVD and hypercholesterolemia.
Read More
Managing ASCVD in Patients With Statin Intolerance
A panel of experts discusses recommendations for managing statin intolerance in patients with hypercholesterolemia.
Read More
Use of Non-statin Therapies in Patients With High Coronary Artery Calcium (CAC) Scores
Pam Taub, MD, FACC, FASPC, shares her thoughts on use of coronary artery calcium (CAC) scores when treating patients with nonstatin therapies.
Read More
Guideline Recommendations for Lipid Lowering
Drs Erin Michos, Pam Taub, Robert Busch, Alison Bailey, and Jorge Plutzky review guidelines and recommendations for using lipid-lowering agents in addition to statins.
Read More